159 related articles for article (PubMed ID: 38349430)
1. Treatment of secondary CNS lymphoma using CD19-targeted chimeric antigen receptor (CAR) T cells.
Kline K; Luetkens T; Koka R; Kallen ME; Chen W; Ahmad H; Omili D; Iraguha T; Gebru E; Fan X; Miller A; Dishanthan N; Baker JM; Dietze KA; Hankey KG; Yared JA; Hardy NM; Rapoport AP; Dahiya S; Atanackovic D
Cancer Immunol Immunother; 2024 Feb; 73(3):45. PubMed ID: 38349430
[TBL] [Abstract][Full Text] [Related]
2. Toxicities and Response Rates of Secondary CNS Lymphoma After Adoptive Immunotherapy With CD19-Directed Chimeric Antigen Receptor T Cells.
Karschnia P; Rejeski K; Winkelmann M; Schöberl F; Bücklein VL; Blumenberg V; Schmidt C; Blobner J; von Bergwelt-Baildon M; Tonn JC; Kunz WG; Subklewe M; von Baumgarten L
Neurology; 2022 May; 98(21):884-889. PubMed ID: 35351785
[TBL] [Abstract][Full Text] [Related]
3. Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells.
Karschnia P; Arrillaga-Romany IC; Eichler A; Forst DA; Gerstner E; Jordan JT; Ly I; Plotkin SR; Wang N; Martinez-Lage M; Winter SF; Tonn JC; Rejeski K; von Baumgarten L; Cahill DP; Nahed BV; Shankar GM; Abramson JS; Barnes JA; El-Jawahri A; Hochberg EP; Johnson PC; Soumerai JD; Takvorian RW; Chen YB; Frigault MJ; Dietrich J
Neuro Oncol; 2023 Dec; 25(12):2239-2249. PubMed ID: 37402650
[TBL] [Abstract][Full Text] [Related]
4. CD19 or CD20 CAR T Cell Therapy Demonstrates Durable Antitumor Efficacy in Patients with Central Nervous System Lymphoma.
Liu R; Cheng Q; Kang L; Wang E; Li Y; Zhang J; Xiao H; Zhang Y; Chu L; Chen X; Zhang C; Tan J; Xu N; Li M; Yu L; Li X
Hum Gene Ther; 2022 Mar; 33(5-6):318-329. PubMed ID: 35152726
[TBL] [Abstract][Full Text] [Related]
5. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials.
Leahy AB; Newman H; Li Y; Liu H; Myers R; DiNofia A; Dolan JG; Callahan C; Baniewicz D; Devine K; Wray L; Aplenc R; June CH; Grupp SA; Rheingold SR; Maude SL
Lancet Haematol; 2021 Oct; 8(10):e711-e722. PubMed ID: 34560014
[TBL] [Abstract][Full Text] [Related]
6. The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma.
Wang X; Huynh C; Urak R; Weng L; Walter M; Lim L; Vyas V; Chang WC; Aguilar B; Brito A; Sarkissian A; Bandara NA; Yang L; Wang J; Wu X; Zhang J; Priceman SJ; Qin H; Kwak LW; Budde LE; Thomas SH; Clark MC; Popplewell L; Siddiqi T; Brown CE; Forman SJ
Cancer Immunol Res; 2021 Jan; 9(1):75-88. PubMed ID: 33093217
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study.
Epperla N; Feng L; Shah NN; Fitzgerald L; Shah H; Stephens DM; Lee CJ; Ollila T; Shouse G; Danilov AV; David KA; Torka P; Hashmi H; Hess B; Barta SK; Romancik JT; Cohen JB; Annunzio K; Kittai AS; Reneau J; Zurko J; Nizamuddin IA; Winter JN; Gordon LI; Ma S; Patel R; Nastoupil L; Ahmed S; Karmali R
J Hematol Oncol; 2023 Nov; 16(1):111. PubMed ID: 37946255
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma.
Zhang H; Yan Z; Wang Y; Qi Y; Hu Y; Li P; Cao J; Zhang M; Xiao X; Shi M; Xia J; Ma S; Qiao J; Li H; Pan B; Qi K; Cheng H; Sun H; Zhu F; Sang W; Li D; Li Z; Zheng J; Zhao M; Liang A; Huang H; Xu K
Front Immunol; 2022; 13():965224. PubMed ID: 36059496
[TBL] [Abstract][Full Text] [Related]
9. Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients.
Cook MR; Dorris CS; Makambi KH; Luo Y; Munshi PN; Donato M; Rowley S; Saad A; Goy A; Dunleavy K; Ali A
Blood Adv; 2023 Jan; 7(1):32-39. PubMed ID: 36260735
[TBL] [Abstract][Full Text] [Related]
10. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
11. Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma.
Zhang W; Huang C; Liu R; Zhang H; Li W; Yin S; Wang L; Liu W; Liu L
Front Immunol; 2022; 13():983934. PubMed ID: 36275715
[TBL] [Abstract][Full Text] [Related]
12. CAR T-cell therapy in large B cell lymphoma.
Boardman AP; Salles G
Hematol Oncol; 2023 Jun; 41 Suppl 1(Suppl 1):112-118. PubMed ID: 37294963
[TBL] [Abstract][Full Text] [Related]
13. Long-term in vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in mice.
Mulazzani M; Fräßle SP; von Mücke-Heim I; Langer S; Zhou X; Ishikawa-Ankerhold H; Leube J; Zhang W; Dötsch S; Svec M; Rudelius M; Dreyling M; von Bergwelt-Baildon M; Straube A; Buchholz VR; Busch DH; von Baumgarten L
Proc Natl Acad Sci U S A; 2019 Nov; 116(48):24275-24284. PubMed ID: 31712432
[TBL] [Abstract][Full Text] [Related]
14. Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review of Literature.
Asghar N; Masood A; Dhaliwal A; Khurana S; Davis J; Hashmi H; Husnain M
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):15-21. PubMed ID: 36328891
[TBL] [Abstract][Full Text] [Related]
15.
Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
Front Immunol; 2022; 13():770132. PubMed ID: 35154098
[TBL] [Abstract][Full Text] [Related]
16. Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma.
Liu Y; Deng B; Hu B; Zhang W; Zhu Q; Liu Y; Wang S; Zhang P; Yang Y; Yang J; Zheng Q; Yu X; Gao Z; Zhou C; Han W; Yang J; Jin L; Tong C; Chang AH; Zhang Y
Blood Adv; 2022 Feb; 6(3):717-730. PubMed ID: 34521107
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19.
Ormhøj M; Scarfò I; Cabral ML; Bailey SR; Lorrey SJ; Bouffard AA; Castano AP; Larson RC; Riley LS; Schmidts A; Choi BD; Andersen RS; Cédile O; Nyvold CG; Christensen JH; Gjerstorff MF; Ditzel HJ; Weinstock DM; Barington T; Frigault MJ; Maus MV
Clin Cancer Res; 2019 Dec; 25(23):7046-7057. PubMed ID: 31439577
[TBL] [Abstract][Full Text] [Related]
18. Cord blood-derived CD19-specific chimeric antigen receptor T cells: an off-the-shelf promising therapeutic option for treatment of diffuse large B-cell lymphoma.
Yu T; Luo C; Zhang H; Tan Y; Yu L
Front Immunol; 2023; 14():1139482. PubMed ID: 37449207
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas.
Chu F; Cao J; Liu J; Yang H; Davis TJ; Kuang SQ; Cheng X; Zhang Z; Karri S; Vien LT; Bover L; Sun R; Vega F; Green M; Davis RE; Neelapu SS
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38007239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
